Paul Matteis

Nabriva Therapeutics AG – ADR (NASDAQ: NBRV) shares have plunged 24 percent since September 21, while hovering close to the $10 mark so far in October. Leerink’s Paul Matteis initiating coverage of the company with an Outperform rating and a price target of $19. Lefamulin sets...

European approval of Orexigen Therapeutics Inc.'s (NASDAQ: OREX) anti-obesity drug sets the stage for an overseas partnership deal, an analyst said. Orexigen, which announced marketing clearance for the product from European regulators late Thursday, closed up 4 percent Friday at $7.54. Shares were...

In a report published Wednesday, Leerink analyst Paul Matteis commented on Orexigen Therapeutics, Inc. (NASDAQ: OREX) and wrote that following a positive opinion from the CHMP, the company expects a final opinion from the EMA on the Mysimba (Contrave) marketing authorization application. Matteis...